Iricryn (Bimatoprost)

Bimatoprost activates prostaglandin F (FP) receptors in the eye’s ciliary muscle, which increases the uveoscleral outflow of aqueous humor. This enhanced drainage lowers the pressure inside the eye, addressing the primary cause of glaucoma‑related vision loss.

The dosing regimen for Iricryn is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and frequency should follow the prescriber’s instructions.

Safety data for bimatoprost in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Iricryn, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iricryn belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intraocular pressure reduction. Compared with beta‑blockers or carbonic anhydrase inhibitors, prostaglandin analogs often have a more favorable dosing schedule but may cause distinctive ocular side effects such as iris darkening.

Iricryn should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light, and avoid exposure to moisture to maintain product stability.

Iricryn is applied as a single drop into the conjunctival sac of the prescribed eye(s) once daily, usually in the evening. Patients should wash their hands before use, avoid touching the tip of the bottle to any surface, and follow any additional instructions from their eye‑care professional.

Serious risks, though rare, include severe ocular inflammation (uveitis or iritis), allergic reactions causing eyelid or conjunctival swelling, sudden loss of vision, and paradoxical increase in intraocular pressure. Any sudden eye pain, redness, or vision changes should prompt immediate medical evaluation.

Iricryn should not be used by individuals with known hypersensitivity to bimatoprost or any formulation ingredient. It is also contraindicated in eyes with active inflammation or infection until these conditions are resolved, and caution is advised in patients with severe asthma or uncontrolled cardiovascular disease.